Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Reports 13-Percent Gain in Q1 Revenues

NEW YORK, April 21 (GenomeWeb News) - Affymetrix today reported a 13-percent gain in total first-quarter revenues as a net loss turned into a profit.

Total receipts for the three months ended March 31 increased to $88.6 million from $78.6 million year over year.

R&D spending at the Santa Clara, Calif.-based microarray seller slid 1 percent to $17.1 million from $17.3 in the year-ago quarter.

As a result, net income for the quarter was $16.2 million, or $.26 per basic share, compared to a net loss of $1.8 million, or $.03 per basic share, in the year-ago quarter.

Affymetrix reaffirmed that it expects to generate around $390 million in product-related revenue in 2005 and said second-quarter receipts should come in at around $87 million, a 9-percent increase over the same period in 2004.

Affymetrix had $63 million cash and cash equivalents on hand as of March 31.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.